DeepBiome Therapeutics
DeepBiome Therapeutics, a US-based biotech firm, leverages deep learning and synthetic biology for innovative drug discovery.
Founded
2017DeepBiome Therapeutics, a US-based biotech firm, leverages deep learning and synthetic biology for innovative drug discovery.
Founded in 2017 and based in Allston, Massachusetts, DeepBiome Therapeutics is a biotechnology company focused on revolutionizing drug discovery. The company's core mission is to unlock the therapeutic potential of the microbiome through advanced technologies such as deep learning and synthetic biology. DeepBiome offers a cutting-edge drug discovery platform that enables pharmaceutical companies to develop new therapies more efficiently and effectively. Their market focus is primarily on the healthcare and pharmaceutical sectors, aiming to address unmet medical needs through innovative solutions.
DeepBiome Therapeutics has garnered attention from notable investors and industry experts, contributing to its rapid growth and recognition in the biotech field. The company has achieved significant milestones, including the successful development of its proprietary platform and partnerships with leading drug companies. Its impact is evident in the advancement of microbiome-based therapies, positioning DeepBiome as a key player in the next generation of drug discovery and development.
Companies similar to DeepBiome Therapeutics include Deep Apple Therapeutics, Biosortia Microbiomics, Absci and DeepCure.
DeepBiome Therapeutics was founded in 2017.
DeepBiome Therapeutics' headquarters is located in Llanura, MA, US.
DeepBiome Therapeutics' most recent funding round was for $2.5M (USD) in July 2019.
As of Jul 26, 2019, DeepBiome Therapeutics has disclosed funding of $2.5M (USD). Undisclosed round amounts are excluded.
DeepBiome Therapeutics has 6 employees as of Feb 5, 2024.
DeepCure
deepcure.ai
